<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04209855</url>
  </required_header>
  <id_info>
    <org_study_id>IMGN853-0416</org_study_id>
    <secondary_id>2019-003509-80</secondary_id>
    <nct_id>NCT04209855</nct_id>
  </id_info>
  <brief_title>A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression</brief_title>
  <acronym>MIRASOL</acronym>
  <official_title>MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImmunoGen, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ImmunoGen, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 3 study is designed to compare the efficacy and safety of mirvetuximab
      soravtansine vs. investigator's choice chemotherapy in patients with platinum-resistant
      high-grade epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer, whose
      tumors express a high-level of FRα. Patients will be, in the opinion of the Investigator,
      appropriate for single-agent therapy for their next line of therapy. Folate receptor alpha
      (FRα) positivity will be defined by the Ventana FOLR1 (FOLR1-2.1) CDx assay.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomized to either mirvetuximab soravtansine (MIRV) or Investigator's
      Choice chemotherapy (paclitaxel, PEGylated liposomal doxorubicin, or topotecan).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 31, 2019</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The time from date of randomization until Investigator-assessed progressive disease or death, whichever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Adverse events (AEs) will be evaluated according to the NCI CTCAE v5.0. AEs will be coded using the latest Medical Dictionary for Regulatory Activities (MedDRA) version and summarized per system organ class (SOC) and preferred term (PT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Objective response includes best response of complete response (CR) or partial response (PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The time from date of randomization until the date of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary patient-reported outcomes</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The number of patients achieving at least 15 point absolute improvement at Week 8 or Week 9 in the abdominal/GI scale of the European Organization for Research and Treatment of Cancer (EORTC) ovarian cancer specific quality of life questionnaire (QLQ-OV28). A higher score represents a better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The time from initial response until Investigator-assessed progressive disease for all patients who achieve a confirmed objective response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CA-125 response</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Serum CA-125 response determined using the GCIG criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival 2 (PFS 2)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The time from date of randomization until second disease progression or death whichever occurs first. Results will be summarized by arm</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Patient-reported outcomes using EORTC QLQ-C30 questionnaires</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The EORTC QLQ-C30 questionnaires will be used to collect data on the patient's functioning, health-related QOL, disease symptoms and health status. A higher score represents a higher response level.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient-reported outcomes using EQ-5D-5L questionnaires</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The EuroQol-5 Dimension 5-level (EQ-5D-5L) questionnaires will be used to collect data on the patient's functioning, health-related QOL, disease symptoms and health status. A higher score represents a higher response level.</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic parameters</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Plasma samples will be collected to determine the concentration of MIRV (antibody-drug conjugate, total antibody, free DM4, S-methyl DM4 and possibly other metabolites). Summary statistics of the concentration at each time point (nominal time) will be presented. Graphical presentation of the data may also be completed using nominal time.</description>
  </other_outcome>
  <other_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The presence of anti-drug antibodies to mirvetuximab soravtansine</description>
  </other_outcome>
  <other_outcome>
    <measure>Identification of soluble FRα levels and other biomarkers</measure>
    <time_frame>Up to 2 years</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">430</enrollment>
  <condition>Epithelial Ovarian Cancer</condition>
  <condition>Peritoneal Cancer</condition>
  <condition>Fallopian Tube Cancer</condition>
  <arm_group>
    <arm_group_label>mirvetuximab soravtansine (MIRV; IMGN853)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MIRV 6 mg/kg adjusted ideal body weight (AIBW) every 3 weeks (Q3W)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Investigator's choice of chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel (Pac; 80 mg/m2) administered once per week (QW) within a 4-week cycle
Pegylated liposomal doxorubicin (PLD; 40 mg/m2) administered every 4 weeks (Q4W)
Topotecan (Topo; 4 mg/m2) administered either on Days 1, 8, and 15 every 4 weeks or for 5 consecutive days (1.25 mg/m2 Days 1-5) every 3 weeks (Q3W)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirvetuximab Soravtansine</intervention_name>
    <description>Mirvetuximab soravtansine is an antibody drug conjugate designed to target folate receptor α (FRα). It consists of the humanized anti-FRα mAb M9346A attached via a cleavable disulfide linker to the cytotoxic maytansinoid, DM4.</description>
    <arm_group_label>mirvetuximab soravtansine (MIRV; IMGN853)</arm_group_label>
    <other_name>MIRV</other_name>
    <other_name>IMGN853</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel is a taxane that can stabilize microtubules to inhibit cell division. It was approved for treatment of recurrent epithelial ovarian cancer.</description>
    <arm_group_label>Investigator's choice of chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topotecan</intervention_name>
    <description>Topotecan induces irreversible DNA damage. It inhibits topoisomerase 1, leading to both single and double strand DNA break that eventually promote apoptosis. Topotecan was approved for treatment of epithelial ovarian cancer after failure of initial or subsequent chemotherapy.</description>
    <arm_group_label>Investigator's choice of chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated liposomal doxorubicin</intervention_name>
    <description>Pegylated liposomal doxorubicin is a standard chemotherapy regimen used for treating platinum-resistant ovarian cancer. The active component doxorubicin is an anthracycline that intercalates DNA, leading to inhibition of replication and subsequently, the inhibition of proper cell division.</description>
    <arm_group_label>Investigator's choice of chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female patients ≥ 18 years of age

          2. Patients must have a confirmed diagnosis of high-grade serous epithelial ovarian
             cancer, primary peritoneal cancer, or fallopian tube cancer

          3. Patients must have platinum-resistant disease (defined as progression within 6 months
             from completion of a minimum of four cycles of platinum-containing therapy) Note: This
             should be calculated from the date of the last administered dose of platinum therapy
             to the date of the radiographic imaging showing progression. Patients who are
             platinum-refractory during front-line treatment are excluded

          4. Patients must have progressed on or after their most recent line of therapy Note:
             Progression must be determined radiographically and/or by CA-125 GCIG progression
             criteria

          5. Patients must be willing to provide an archival tumor tissue block or slides, or
             undergo procedure to obtain a new biopsy using a low risk, medically routine procedure
             for IHC confirmation of FRα positivity

          6. Patient's tumor must be positive for FRα expression as defined by the Ventana FOLR1
             (FOLR-2.1) CDx assay

          7. Patients must have at least one lesion that meets the definition of measurable disease
             by RECIST v1.1 (radiologically measured by the Investigator)

          8. Patients must have received at least 1 but no more than 3 prior systemic lines of
             anticancer therapy, and for whom single-agent therapy is appropriate as the next line
             of treatment:

               1. Adjuvant ± neoadjuvant considered one line of therapy

               2. Maintenance therapy (eg, bevacizumab, PARP inhibitors) will be considered as part
                  of the preceding line of therapy (ie, not counted independently)

               3. Therapy changed due to toxicity in the absence of progression will be considered
                  as part of the same line (ie, not counted independently)

               4. Hormonal therapy will be counted as a separate line of therapy unless it was
                  given as maintenance

          9. Patient must have an Eastern Cooperative Oncology Group Performance Status (ECOG PS)
             of 0 or 1

         10. Time from prior therapy:

               1. Systemic antineoplastic therapy (5 half-lives or 4 weeks, whichever is shorter)

               2. Focal radiation completed at least 2 weeks prior to first dose of study drug

         11. Patients must have stabilized or recovered (Grade 1 or baseline) from all prior
             therapy-related toxicities

         12. Major surgery must be completed at least 4 weeks prior to first dose and have
             recovered or stabilized from the side effects of prior surgery

         13. Patients must have adequate hematologic, liver and kidney functions defined as:

               1. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L (1,500/μL)

               2. Platelet count ≥ 100 x 109/L (100,000/μL) without platelet transfusion in the
                  prior 10 days

               3. Hemoglobin ≥ 9.0 g/dL

               4. Serum creatinine ≤ 1.5 x upper limit of normal (ULN)

               5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 x ULN

               6. Serum bilirubin ≤ 1.5 x ULN (patients with documented diagnosis of Gilbert
                  syndrome are eligible if total bilirubin &lt; 3.0 x ULN

               7. Serum albumin ≥ 2 g/dL

         14. Patients or their legally authorized representative must be willing and able to sign
             the informed consent form (ICF) and to adhere to the protocol requirements

         15. Women of childbearing potential (WCBP) must agree to use highly effective
             contraceptive method(s) (as defined in Section 5.9.6 in the protocol) while on study
             drug and for at least 3 months after the last dose of MIRV or at least 6 months after
             the last dose of paclitaxel, pegylated liposomal doxorubicin, or topotecan

         16. WCBP must have a negative pregnancy test within 4 days prior to the first dose of
             study drug

        Exclusion Criteria:

          1. Patients with endometrioid, clear cell, mucinous, or sarcomatous histology, mixed
             tumors containing any of the above histologies, or low-grade or borderline ovarian
             tumor

          2. Patients with primary platinum-refractory disease, defined as disease that did not
             respond to or has progressed within 3 months of the last dose of first line
             platinum-containing chemotherapy

          3. Patients with prior wide-field RT affecting at least 20% of the bone marrow

          4. Patients with &gt; Grade 1 peripheral neuropathy per CTCAE v5.0

          5. Patients with active or chronic corneal disorders, history of corneal transplantation,
             or active ocular conditions requiring ongoing treatment/monitoring such as
             uncontrolled glaucoma, wet age-related macular degeneration requiring intravitreal
             injections, active diabetic retinopathy with macular edema, macular degeneration,
             presence of papilledema, and /or monocular vision

          6. Patients with serious concurrent illness or clinically relevant active infection,
             including, but not limited to the following:

               1. Active hepatitis B or C infection (whether or not on active antiviral therapy)

               2. HIV infection

               3. Cytomegalovirus infection

               4. Any other concurrent infectious disease requiring IV antibiotics within 2 weeks
                  before starting study drug

          7. Patients with history of multiple sclerosis or other demyelinating disease and/or
             Lambert-Eaton syndrome (paraneoplastic syndrome)

          8. Patients with clinically significant cardiac disease including, but not limited to,
             any one of the following:

               1. Myocardial infarction ≤ 6 months prior to first dose

               2. Unstable angina pectoris

               3. Uncontrolled congestive heart failure (New York Heart Association &gt; class II)

               4. Uncontrolled ≥ Grade 3 hypertension (per CTCAE)

               5. Uncontrolled cardiac arrhythmias

          9. Patients assigned to PLD stratum only: Left ventricular ejection fraction (LVEF) below
             the institutional limit of normal as measured by echocardiography (ECHO) or multigated
             acquisition (MUGA) scan

         10. Patients with a history of hemorrhagic or ischemic stroke within six months prior to
             randomization

         11. Patients with a history of cirrhotic liver disease (Child-Pugh Class B or C)

         12. Patients with a previous clinical diagnosis of non-infectious interstitial lung
             disease (ILD), including noninfectious pneumonitis

         13. Patients with required use of folate-containing supplements (eg, folate deficiency)

         14. Patients with prior hypersensitivity to monoclonal antibodies

         15. Women who are pregnant or lactating

         16. Patients with prior treatment with MIRV or other FRα-targeting agents

         17. Patients with untreated or symptomatic central nervous system (CNS) metastases

         18. Patients with a history of other malignancy within 3 years prior to randomization.
             Note: does not include tumors with a negligible risk for metastasis or death (eg,
             adequately controlled basal-cell carcinoma or squamous-cell carcinoma of the skin, or
             carcinoma in situ of the cervix or breast
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick A Zweidler-McKay, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>ImmunoGen, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elizabeth Noble</last_name>
    <phone>781-895-0176</phone>
    <email>Elizabeth.Noble@immunogen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Oncology Associates, PC - HAL - USOR</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Beers</last_name>
      <phone>602-277-4868</phone>
      <email>wendy.beers@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Bradley Monk</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USOR: Arizona Oncology Associates, PC - HOPE</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Robertson</last_name>
      <phone>520-886-0206</phone>
      <email>linda.robertson@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Joseph Buscema</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA - JCCC Dept of OBGYN - Women's Health Clinical Research Unit</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaushali Thakone-Shah</last_name>
      <phone>310-794-9652</phone>
      <email>KThakoreShah@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Gottfried Konecny</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USOR: Rocky Mountain Cancer Centers</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80228</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Dollarhide</last_name>
      <phone>303-430-2700</phone>
      <email>susan.dollarhide@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Ling Ma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Women's Care Florida / Women's Cancer Associates</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Whitaker</last_name>
      <phone>727-826-0792</phone>
      <email>awhitaker@womenscarefl.com</email>
    </contact>
    <investigator>
      <last_name>Megan D. Indermaur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarasota Memorial Hospital</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Hill</last_name>
      <phone>941-917-8789</phone>
      <email>sharon-hill@smh.com</email>
    </contact>
    <investigator>
      <last_name>James Fiorica</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial University Medical Center</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Morgan</last_name>
      <phone>912-350-7878</phone>
      <email>lisa.morgan2@hcahealthcare.com</email>
    </contact>
    <investigator>
      <last_name>James Burke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois Cancer Specialists</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Glidden</last_name>
      <phone>847-259-4482</phone>
      <email>andrea.glidden@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Urszula Sobol</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Penelope Dolan</last_name>
      <phone>773-702-3394</phone>
      <email>pdolan@bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>John Moroney</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr. Sudarshan K. Sharma, Ltd.</name>
      <address>
        <city>Hinsdale</city>
        <state>Illinois</state>
        <zip>60521</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peg Gregus</last_name>
      <phone>630-601-7719</phone>
      <email>drsharma@ameritech.net</email>
    </contact>
    <investigator>
      <last_name>Sharma Sudarshan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslye Adams</last_name>
      <phone>502-899-3366</phone>
      <phone_ext>19230</phone_ext>
      <email>Leslye.Adams@nortonhealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Mary Gordinier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>WK Physicians Network/Gynecologic Oncology Associates</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>771103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Kay</last_name>
      <phone>318-212-8130</phone>
      <email>ckay@wkhs.com</email>
    </contact>
    <investigator>
      <last_name>Destin Black, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Holy Cross Hospital</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lyudmila Kalnitskaya</last_name>
      <phone>301-754-7552</phone>
      <email>kalnitsl@holycrosshealth.org</email>
    </contact>
    <investigator>
      <last_name>James Barter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USOR: Maryland Oncology Hematology, P.A.</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Imaan Khan</last_name>
      <phone>301-942-9220</phone>
      <email>imaan.khan@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Cheryl Aylesworth</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Dinh</last_name>
      <phone>617-636-8885</phone>
      <email>mdinh1@tuftsmedicalcenter.org</email>
    </contact>
    <investigator>
      <last_name>John Schorge</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baystate Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Sorci</last_name>
      <phone>413-794-3188</phone>
      <email>Laura.Sorci@baystatehealth.org</email>
    </contact>
    <investigator>
      <last_name>Tashanna Myers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dawn Pepka-Jones</last_name>
      <phone>508-334-1160</phone>
      <email>Dawn.Pepka-Jones@umassmemorial.org</email>
    </contact>
    <investigator>
      <last_name>Susan Zweizig</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison Wolgast</last_name>
      <phone>313-576-8994</phone>
      <email>wolgasta@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Robert Morris</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USOR: Minnesota Oncology Hematology, PA</name>
      <address>
        <city>Woodbury</city>
        <state>Minnesota</state>
        <zip>55125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Rabenn</last_name>
      <phone>651-735-7414</phone>
      <email>anne.rabenn@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Jessica Thomes-Pepin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Valley Hospital, Inc</name>
      <address>
        <city>Ridgewood</city>
        <state>New Jersey</state>
        <zip>07450</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kasey Bessada</last_name>
      <phone>201-634-5792</phone>
      <email>kbessad@valleyhealth.com</email>
    </contact>
    <investigator>
      <last_name>Eleonora Teplinsky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Holy Name Medical Center</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marissa VanOrden</last_name>
      <phone>201-541-6312</phone>
      <email>mvanorden@holyname.org</email>
    </contact>
    <investigator>
      <last_name>Sharyn Lewin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FirstHealth of the Carolinas Outpatient Cancer Center</name>
      <address>
        <city>Pinehurst</city>
        <state>North Carolina</state>
        <zip>28374</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Mason</last_name>
      <phone>910-715-2213</phone>
      <email>pmason@firsthealth.org</email>
    </contact>
    <investigator>
      <last_name>Michael Sundborg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USOR: OHC - Oncology_Hematology Care Clinical Trials, Inc.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Clary</last_name>
      <phone>513-751-2273</phone>
      <phone_ext>27124</phone_ext>
      <email>nicole.clary1@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Cynthia Chua</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Cooper</last_name>
      <phone>405-271-8001</phone>
      <email>Sarah-Cooper@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Kathleen Moore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oklahoma Cancer Specialists and Research Institute</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Powell</last_name>
      <phone>918-505-3304</phone>
      <email>melissa.powell@ocsri.org</email>
    </contact>
    <investigator>
      <last_name>Michael Gold</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USOR: Willamette Valley Cancer Institute and Research Center</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luisa Salter</last_name>
      <phone>541-683-5001</phone>
      <email>luisa.salter@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Charles Anderson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USOR: Northwest Cancer Specialists, P.C.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julian Kern</last_name>
      <phone>360-597-1316</phone>
      <email>Julian.Kern@compassoncology.com</email>
    </contact>
    <investigator>
      <last_name>Erin Salinas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reshma Shelat</last_name>
      <phone>215-214-1753</phone>
      <email>Reshma.Shelat@fccc.edu</email>
    </contact>
    <investigator>
      <last_name>Gina Mantia-Smaldone</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Magee-Women's Hospital-UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>steeleb@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Brian Orr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Penn Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Baldauf</last_name>
      <phone>412-578-4517</phone>
      <email>erin.baldauf@ahn.org</email>
    </contact>
    <investigator>
      <last_name>Thomas Krivak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Women &amp; Infants Hospital of Rhode Island</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann John</last_name>
      <phone>401-274-1122</phone>
      <phone_ext>48181</phone_ext>
      <email>ajohn@wihri.org</email>
    </contact>
    <investigator>
      <last_name>Matthew Oliver</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USOR: Texas Oncology-South Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Janeczko</last_name>
      <phone>512-447-2202</phone>
      <email>patricia.janeczko@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Michael Teneriello</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USOR: Texas Oncology - Fort Worth Cancer Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina Morris</last_name>
      <phone>817-413-1500</phone>
      <email>tina.morris@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Noelle Cloven</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USOR: Texas Oncology - McAllen South Second</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nereida Salinas</last_name>
      <phone>956-969-0021</phone>
      <email>nereida.salinas@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Suresh Ratnam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USOR: Texas Oncology - San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debbie Ponce</last_name>
      <phone>210-595-5300</phone>
      <email>debbie.ponce@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Antonio Santillan-Gomez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USOR: Texas Oncology, P.A.</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Howell</last_name>
      <phone>281-276-3413</phone>
      <email>melissa.howell@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Kristy Ward</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USOR: Texas Oncology - The Woodlands, Gynecologic Oncology</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth Lopez</last_name>
      <phone>281-296-0365</phone>
      <email>ruth.lopez1@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Christine Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USOR: Texas Oncology - Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>K. Shelly Maxfield</last_name>
      <phone>903-579-9801</phone>
      <email>shelly.maxfield@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Donald Richards</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USOR: Texas Oncology, P.A.</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tara Gray</last_name>
      <phone>281-332-7505</phone>
      <email>Tara.Gray@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Terri Pustilnik</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Gabel</last_name>
      <phone>434-982-6657</phone>
      <email>am7bd@hscmail.mcc.virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Linda Duska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USOR: Virginia Cancer Specialists, PC</name>
      <address>
        <city>Gainesville</city>
        <state>Virginia</state>
        <zip>20155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jutta McGovern</last_name>
      <phone>571-222-2200</phone>
      <email>jutta.mcgovern@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Robert Marsh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kadlec Clinic Hematology &amp; Oncology</name>
      <address>
        <city>Kennewick</city>
        <state>Washington</state>
        <zip>99336</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corey Brumbaugh</last_name>
      <phone>509-783-4637</phone>
      <email>Corey.Brumbaugh@kadlec.org</email>
    </contact>
    <investigator>
      <last_name>Zhuo Ying</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Virginia University- MBRCC</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Moore</last_name>
      <phone>304-293-0609</phone>
      <email>deborah.moore@hsc.wvu.edu</email>
    </contact>
    <investigator>
      <last_name>Valerie Galvan-Turner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Newcastle Private Hospital</name>
      <address>
        <city>New Lambton Heights</city>
        <state>New South Wales</state>
        <zip>2305</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clare Fischer</last_name>
      <phone>(02) 4941 8718</phone>
      <email>Clare.Fischer@healthscope.com.au</email>
    </contact>
    <investigator>
      <last_name>Antonino Bonaventura</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 17, 2019</study_first_submitted>
  <study_first_submitted_qc>December 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2019</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Platinum-resistant</keyword>
  <keyword>Folate-receptor alpha expression</keyword>
  <keyword>Phase 3</keyword>
  <keyword>Antibody-drug conjugate</keyword>
  <keyword>mirvetuximab soravtansine</keyword>
  <keyword>IMGN853</keyword>
  <keyword>Epithelial Ovarian Cancer</keyword>
  <keyword>Peritoneal Cancer</keyword>
  <keyword>Fallopian Tube Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Maytansine</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

